Registered title, quoted from ClinicalTrials.gov
Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma
An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Jiangsu Province Hospital; 6 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 7
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Lead sponsorJiangsu Province Hospital江苏省人民医院(南医大一附院)NanjingHospital page
- Study siteAffiliated Hospital of Qingdao University青岛大学附属医院QingdaoHospital page
- Study siteFirst Affiliated Hospital of Soochow University苏州大学附属第一医院SuzhouHospital page
- Study siteFourth Hospital of Hebei Medical University河北医科大学第四医院ShijiazhuangHospital page
- Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page
- Study siteJiangsu Cancer Hospital江苏省肿瘤医院NanjingHospital page
- Study siteNanjing Drum Tower Hospital南京鼓楼医院NanjingHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07902596, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 3
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (3 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Histologically confirmed gastric adenocarcinoma or esophagogastric junction adenocarcinoma.
Inclusion criterion 2
Identifiable surgical procedure and evaluable station-specific lymph node pathological records.
Inclusion criterion 7
Final preoperative imaging assessment within four weeks before surgery with evaluable ycT and ycN categories according to the AJCC/UICC eighth edition.
Inclusion criterion 4
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07902596, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age 18 years or older.
- Histologically confirmed gastric adenocarcinoma or esophagogastric junction adenocarcinoma.
- Completion of at least two cycles of neoadjuvant chemotherapy, chemotherapy combined with immunotherapy, or chemoradiotherapy.
- Final preoperative imaging assessment within four weeks before surgery with evaluable ycT and ycN categories according to the AJCC/UICC eighth edition.
- ycM0 disease before surgery.
- R0 curative-intent total, distal, or proximal gastrectomy with lymph node dissection.
- Identifiable surgical procedure and evaluable station-specific lymph node pathological records.
- Surgery performed between January 1, 2021, and August 30, 2026.
Exclusion Criteria:
- Histological diagnosis other than adenocarcinoma, including squamous cell carcinoma, lymphoma, gastrointestinal stromal tumor, or neuroendocrine neoplasm.
- Conversion therapy for initially unresectable or metastatic disease.
- Intraperitoneal hyperthermic perfusion treatment.
- ycM1 disease, including peritoneal, hepatic, or other distant metastasis.
- R1 or R2 resection, palliative surgery, or exploratory surgery without curative gastrectomy.
- Previous gastrectomy.
- Synchronous multiple primary gastric cancers.
- Another active malignant tumor.
- Missing core data required for eligibility or the primary analysis, including ycT, ycN, gastrectomy type, or station-specific pathological records.
Quoted from ClinicalTrials.gov, NCT07902596, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07902596, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.